Fig. 3 | Scientific Reports

Fig. 3

From: Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study

Fig. 3

Survival analysis for patients with International Metastatic RCC Database Consortium (IMDC) favorable/intermediate- and those with poor- risk. Kaplan-Meier curve of (A) progression-free survival (PFS) and (B) overall survival (OS) in patients with IMDC favorable/intermediate- (n = 87) and poor-risk (n = 31) groups. (C) Comparative analysis of baseline C-reactive protein levels between IMDC poor- and favorable/intermediate risk-groups.

Back to article page